YI 111, Inc. Annual reports only
Retail-Drug Stores and Proprietary Stores · Nasdaq · SEC CIK 1738906 · Reporting currency CNY · Fiscal year ends 12/31
Financial factors as of 2021-12-31 (FY2021), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY51.5%
TTM net income YoY-27.0%
TTM EPS YoY-45.8%
Revenue 3-yr CAGR90.9%
Net income 3-yr CAGR—
Margins
Gross margin5.0%
Operating margin-5.2%
Net margin-4.8%
FCF margin-6.0%
EBITDA margin-4.9%
Returns
ROE-644.5%
ROA-19.2%
ROIC (approx.)—
Asset turnover4.03x
Leverage & solvency
Liabilities / assets73.0%
Debt / equity—
Current ratio1.32x
Interest coverage-117.01x
Cash quality & payout
Operating cash flow / net income1.16x
Accruals ratio3.1%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CNY | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 12.56B | 14.40B | 14.95B | 13.52B | 12.43B |
| Cost of revenue | 11.83B | 13.57B | 14.10B | 12.68B | 11.80B |
| Gross profit | 723.41M | 829.23M | 848.98M | 839.98M | 621.10M |
| SG&A expense | 69.46M | 70.91M | 224.20M | 205.62M | 206.98M |
| Operating income | -2.38M | 2.11M | -350.10M | -371.00M | -642.14M |
| Interest expense | 35.57M | 28.33M | 20.14M | 13.44M | 5.49M |
| Pretax income | -22.50M | -20.68M | -353.18M | -376.07M | -621.02M |
| Income tax | 13,000 | 96,000 | 251,000 | 0 | 0 |
| Net income | -18.42M | -12.38M | -336.60M | -360.79M | -593.21M |
| EBITDA | 9.46M | 19.08M | -328.32M | -330.18M | -614.92M |
| EPS (basic) | -0.38 | -0.38 | -2.33 | -2.50 | -4.04 |
| EPS (diluted) | -0.38 | -0.38 | -2.33 | -2.50 | -4.04 |
| Weighted avg. shares (diluted) | 174.03M | 171.84M | 168.61M | 166.63M | 165.87M |
| Balance sheet | |||||
| Cash & equivalents | 510.97M | 462.29M | 603.52M | 716.79M | 760.67M |
| Short-term investments | 50.03M | — | 50.14M | 205.86M | 182.56M |
| Receivables | 259.69M | 413.10M | 536.82M | 488.88M | 404.47M |
| Inventory | 998.47M | 1.39B | 1.42B | 1.50B | 1.12B |
| Current assets | 2.12B | 2.65B | 2.93B | 3.24B | 2.80B |
| PP&E, net | 21.11M | 32.90M | 34.34M | 48.50M | 80.25M |
| Intangibles | 868,000 | 1.44M | 2.26M | 3.27M | 4.91M |
| Total assets | 2.20B | 2.79B | 3.09B | 3.47B | 3.15B |
| Current liabilities | 1.95B | 2.34B | 2.75B | 2.73B | 2.13B |
| Short-term debt | 187.63M | 160.98M | 338.07M | 178.99M | 259.66M |
| Total liabilities | 1.99B | 2.41B | 2.81B | 2.83B | 2.30B |
| Shareholders' equity | -702.23M | -642.64M | -583.45M | -414.60M | -173.32M |
| Cash flow statement | |||||
| Operating cash flow | 119.14M | 263.02M | -447.24M | -23.15M | -688.84M |
| Capital expenditure | 4.45M | 15.20M | 9.82M | 31.57M | 62.59M |
| Free cash flow | 114.69M | 247.82M | -457.07M | -54.73M | -751.43M |
| Investing cash flow | -53.72M | 37.38M | 151.74M | -47.17M | 60.14M |
| Financing cash flow | -21.19M | -406.24M | 205.98M | 22.73M | 74.34M |
| Depreciation & amortization | 11.84M | 16.97M | 21.78M | 40.82M | 27.22M |
| Stock-based compensation | 10.05M | 20.15M | 226.69M | 162.07M | 145.59M |
| Share buybacks | — | — | — | — | 5.89M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, CNY, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.